Tezepelumab (Tezspire)


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class.
 The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec.
 This review assesses Tezepelumab (Tezspire), 210 mg, 110 mg/mL solution for subcutaneous injection.
 Indication (proposed): indicated an add-on maintenance treatment in adults adolescents 12 years older severe asthma.